Compare Advanced Micro Devices (AMD) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Advanced Micro Devices vs Viatris Inc — how do they compare? Advanced Micro Devices trades at $483.2 (market cap $774.32B), while Viatris Inc trades at $16.28 (market cap $18.69B). The key difference: Advanced Micro Devices is far larger — about 41.4× Viatris Inc's market cap, and Viatris Inc pays a 2.95% dividend while Advanced Micro Devices pays none. Which is the better fit depends on your goals.
| AMD | VTRS | |
|---|---|---|
Market Cap | $774.32B | $18.69B |
Sector | Technology | Health |
52-Week High | $580.91 | $17.86 |
52-Week Low | $151.14 | $9.49 |
Enterprise Value | $765.48B | $30.80B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMD's stock trades at $469.56, down 2.86% over 24 hours, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.66, and shows robust revenue growth, with 2025 revenue reaching $34.64 billion and net income of $4.34 billion. Valuation ratios remain elevated, with a P/E of 121 and P/S of 18.94, reflecting high market expectations amid surging AI demand.
Outlook is supported by AI-driven growth and consistent earnings beats, but risks include intense competition and rich valuations. Analysts maintain a bullish consensus with a $619.54 price target, though near-term volatility may persist due to technical pressure and macroeconomic factors.
Viatris (VTRS) trades at $16.105, down 1.07% on the day, with a bearish technical signal and mixed fundamentals. Recent Q2 2026 earnings beat estimates with EPS of $0.69 and revenue growth of 5%, but the company posted a net loss of $3.51B in 2025. Positive developments include FDA approval for Gwyn Lo and a raised 2026 outlook, though debt remains elevated at $14.04B long-term.
Outlook is cautious; while operational cash flow is strong at $2.32B and dividends provide income, persistent net losses and high P/E of 236.2 signal overvaluation risks. Analyst consensus leans Hold (61.54%), with upside potential if turnaround gains traction, but investors face headwinds from generic drug pricing pressures and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Advanced Micro Devices
Advanced Micro Devices, Inc. (AMD) produces semiconductor products and devices. The Company offers products such as microprocessors, embedded microprocessors, chipsets, graphics, video and multimedia products and supplies it to third-party foundries, as well as provides assembling, testing, and packaging services. AMD serves customers worldwide.
Read more on AMD →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
